231 related articles for article (PubMed ID: 24117862)
1. The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers.
Shida Y; Takahashi N; Sakamoto T; Ino H; Endo A; Hirama T
J Clin Pharm Ther; 2014 Feb; 39(1):97-101. PubMed ID: 24117862
[TBL] [Abstract][Full Text] [Related]
2. Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.
Struemper H; Murtaugh T; Gilbert J; Barton ME; Fire J; Groark J; Fox NL; Roth D; Gordon D
Clin Pharmacol Drug Dev; 2016 May; 5(3):208-15. PubMed ID: 27163500
[TBL] [Abstract][Full Text] [Related]
3. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
Struemper H; Thapar M; Roth D
Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study.
Meng X; Wang Q; Wu S; Pu D; Zhang A; Fang S; Zhou X; Lu H
Rheumatol Ther; 2021 Dec; 8(4):1711-1724. PubMed ID: 34554352
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.
Dimelow R; Ji B; Struemper H
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):622-633. PubMed ID: 33245847
[TBL] [Abstract][Full Text] [Related]
7. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.
Sheikh SZ; Hammer AE; Fox NL; Groark J; Struemper H; Roth D; Gordon D
Int J Clin Pharmacol Ther; 2016 Nov; 54(11):914-922. PubMed ID: 27668697
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus.
Yamada M; Akita M; Nakagawa T; Takahashi N; Endo A; Yoshida P
J Drug Assess; 2013; 2(1):40-8. PubMed ID: 27536436
[TBL] [Abstract][Full Text] [Related]
10. Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus.
Dashiell-Aje E; Harding G; Pascoe K; DeVries J; Berry P; Ramachandran S
Patient; 2018 Feb; 11(1):119-129. PubMed ID: 28956281
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.
Zhu Y; Wang Q; Frederick B; Bouman-Thio E; Marini JC; Keen M; Petty KJ; Davis HM; Zhou H
Clin Drug Investig; 2013 Apr; 33(4):291-301. PubMed ID: 23512638
[TBL] [Abstract][Full Text] [Related]
12. A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men.
Sakamoto K; Matsuki S; Irie S; Uchida N; Hayashi N; Horiuchi M; Ren S
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):833-840. PubMed ID: 31960624
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies.
Joseph D; Thoma C; Haeufel T; Li X
Clin Pharmacokinet; 2022 Dec; 61(12):1771-1787. PubMed ID: 36451029
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.
Chatham W; Chadha A; Fettiplace J; Kleoudis C; Bass D; Roth D; Gordon D
Lupus; 2017 Dec; 26(14):1483-1490. PubMed ID: 28467293
[TBL] [Abstract][Full Text] [Related]
16. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study.
Zhang J; Wan W; Miao L; Wu J; Dong J; Shen Y; Xiong C; Li C; Xue Y; Cao G; Ma P
Rheumatol Ther; 2020 Mar; 7(1):191-200. PubMed ID: 31953740
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Othman AA; Tran JQ; Tang MT; Dutta S
Clin Pharmacokinet; 2014 Oct; 53(10):907-18. PubMed ID: 25212703
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
Portron A; Jordan P; Draper K; Muenzer C; Dickerson D; van Iersel T; Hofmann C
Clin Ther; 2020 Jan; 42(1):108-120.e1. PubMed ID: 31883703
[TBL] [Abstract][Full Text] [Related]
20. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
